NCT00457418View on ClinicalTrials.gov

High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

February 20, 2007

Primary Completion Date

May 27, 2008

Study Completion Date

July 11, 2012

Conditions

Melanoma

Interventions

DRUG

PEG-Intron

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00457418 - High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2) | Biotech Hunter | Biotech Hunter